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ABSTRACT
Background: Variceal esophagus' risk of re-bleeding in the first year is 60-70%. Mortality rate of acute bleeding 
is 20-35%. Latest guidelines of esophageal rupture suggest endoscopic ligation and Non-selective β-Blocker 
combination for re-bleeding prevention. However, monotherapy still can be chosen, depends on the clinical judgement 
and patient preference. The previous meta-analysis still gave inconclusive results on therapy combination effectivity. 
Moreover, there is no side effect discussion between both treatment choices. Hence, this evidence-based case report 
analyses the effectivity of combination treatment for esophageal bleeding secondary prevention. 
Method: Literature searching in Scopus, ProQuest, PubMed, ScienceDirect, and EBSCOhost used keywords 
and their synonyms. Three articles selected included two meta-analyses and one RCT. Critical appraisal on 
validity, importance, and applicability based on Oxford Center of EBM 2011 was conducted.
Results: Two meta-analysis prove treatment combination is significantly effective decreasing variceal re-
bleeding. Ravipati et al. results in RR 0.601 (95% CI: 0.44 - 0.82). However, Kumar et al. shows non-significant 
result. On the other hand, three articles show that therapy combination failed to significantly lower the mortality 
rates RR 0,786 (95% CI: 0,45 - 1,39). This is due to the limitation of treatment combination to prevent cirrhotic 
progression and other complications. Moreover, this also is due to contraindications and non-suitability of the 
patients toward non-selective β-Blocker in 30-40% cases.
Conclusion: Endoscopic ligation and non-selective β-Blocker combination is recommended for variceal 
esophagus bleeding secondary prevention, but other treatments are needed to lower the mortality rate1.
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ABSTRAK 
Latar belakang: Risiko terjadinya perdarahan varises ulang dapat terjadi dalam 1 tahun pertama sebanyak 
60-70% kasus, sedangkan mortalitas akibat perdarahan akut mencapai 20-35% kasus. Algoritma penanganan 
perdarahan variseal mulai merekomendasikan terapi kombinasi ligasi endoskopik dengan terapi Beta blocker 
nonselektif, namun monoterapi dapat diberikan sesuai penilaian klinis dan pereferensi pasien. Beberapa meta-
analisis sebelumnya masih menunjukkan hasil yang inkonklusif. Selain itu, belum terbahas mengenai efek 
samping antara monoterapi dengan terapi kombinasi. Maka dari itu, dilakukan laporan kasus berbasis bukti 
yang menelaah efektivitas penggunaan kombinasi terapi untuk pencegahan sekunder perdarahan variseal akut.
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Metode: Pencarian literatur dilakukan dari Scopus, ProQuest, PubMed, ScienceDirect, dan EBSCOhost 
dengan menggunakan kata kunci beserta istilah lainn yang terkait. Seleksi menghasilkan 2 artikel meta-analisis 
dan 1 artikel Randomized Controlled Trial. Literatur terpilih ditelaah kritis berdasarkan Oxford CEEBM Critical 
Appraisal Tools, meninjau aspek validity, importance, dan applicability.  
Hasil: Dua meta-analisis membuktikan terapi kombinasi signifikan efektif dalam pencegahan perdarahan 
variseal berulang. Pada Ravipati et al RR = 0,601 (95% CI: 0,44-0,82). Namun Kumar et al. memberikan hasil 
yang tidak signifikan. Dibuktikan pada ketiga artikel bahwa terapi kombinasi tidak menurunkan mortalitas 
secara signifikan. RR = 0,786 (95% CI: 0,45-1,39) Hal ini karena ketidakmampuan terapi kombinasi mencegah 
progresi sirosis dan komplikasinya walaupun mencegah perdarahan variseal sirotik berulang. Selain itu juga 
berkaitan dengan kecocokan dan kontraindikasi pasien, yakni sebanyak 30-40%.
Simpulan: Kombinasi ligasi variseal endoskopik dengan β-Blocker non selektif direkomendasikan untuk 
pencegahan sekunder perdarahan varises esofagus sirotik.
Kata kunci: ligasi variseal endoskopik, β-blocker non selektif, perdarahan varises esofaus, pencegahan 
sekunder perdarahan variseal.
INTRODUCTION
Variceal esophagus bleeding is one of severe 
complications of portal hypertension Initial treatment 
of acute bleeding control is followed by the high risk 
of future rebleeding.1,2 Without any further adequate 
management, 60-70% variceal re-bleeding cases will 
occur in the first year and 30-40% in the first six 
months.2 Mortality of variceal esophagus bleeding 
reaches approximately 20-35%.2 Hence, Secondary 
prevention procedures for survived patient from acute 
variceal bleeding are proposed.
In many years, ß-Blocker pharmacotherapy 
and endoscopic sclerotherapy was the first line of 
treatment and prevention of variceal rebleeding.3 
Then, endoscopic variceal ligation was proven to 
be chosen treatment as it increased the safety and 
efficacy on variceal esophagus treatment.3 Besides, 
pharmacology treatment is also developing nowadays. 
Both endoscopic ligation and pharmacological 
treatments work in different mechanism, where 
they could decrease portal tension and eradicate 
local varices.3 Thus, both treatments have potential 
to be additively combined. This principal has been 
researched through clinical trials. Moreover, ß-Blocker 
therapy could add protection effect on recurrent 
bleeding before the next obliteration step of variceal 
ligation.1,3 
The latest algorithm in variceal esophagus 
bleeding management guidelines starts to recommend 
the combination of both treatments.4 However, 
monotherapy (endoscopic ligation or pharmacotherapy 
alone) still can be chosen for the patient based on 
clinical judgement and patient preference.4 Some 
previous meta-analysis gave inconclusive results 
to decide which treatment alternative is the best. 
Moreover, different side effects of both choices have 
not been discussed and compared in the previous 
researches.1,2 
Hence, this evidence-based case report is made from 
the latest articles to study the efficacy of combination 
therapy compared to endoscopic ligation monotherapy 
as secondary prevention of acute variceal esophagus 
bleeding. 
CLINICAL QUESTION
A 49 years old male patient came to Cipto 
Mangunkusumo Hospital with hematemesis 2 hours 
prior to admission. Hematemesis was in the form 
of fresh blood without any food, 250 cc volume, 
and happened without any specific trigger. His first 
hematemesis was 2 months prior to admission, with 
approximately 600 cc fresh blood. Then, patient was 
in pale appearance and lethargy. He was stabilized 
in Tangerang General Hospital Emergency Unit, 
then deny any further treatment. Six months prior to 
admission, patient realized icteric appearance on both 
eyes and skin, with intermittent fever. Sometimes, he 
realized melena in his defecations. He denies any pale 
feces and dark brown urine.
From physical examination, there was tachycardia, 
icteric sclera, gynecomastia, schuffner 3 splenomegaly, 
increased bowel sound (14 times per minute), and 
palmar erythema. 
Laboratory examination showed prothrombin 
time (PT)/activated partial thromboplastin time 
(APTT) increments, aspartate aminotransferase 
(AST)/alanine aminotransferase (ALT) increments, 
non-reactive HBsAg and non-reactive AntiHCV. 
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Esophagogastroduodenoscopy showed grade 3 
varices esophagus, gastropathy, and erosive gastritis. 
Ultrasonography (USG) showed splenomegaly without 
any thrombus. Then, Fibroscan resulted on F2-F3 
hepatitis non B non C.
Patient was diagnosed with grade 3 esophagus 
varices, non B non C hepatic cirrhosis (Child Pugh 
A) and erosive gastritis. Abdominal angiography 
computed tomography (CT) scan was planned for this 
patient. Pharmacological therapy given to the patient 
included intravenous fluid drops (IVFD) asering 500 
mL/24 hours, somatostatin bolus 100 mcg, vitamin 
K 3x10 mg, tranexamic acid 3x1000 mg, cefotaxime 
3x1g, and lansoprazole 1x30 mg, sucralfate 3x15 mL. 
Non-pharmacological therapy on this patient was 1700 
kcal/day diet. Esophagogastroduodenoscopy (EGD) 
with endoscopic variceal ligation was then planned 
for this patient.
In patient with variceal esophagus bleeding, how 
is non-selective ß-Blocker and endoscopic variceal 
ligation combination therapy compared to endoscopic 
ligation monotherapy for secondary prevention on 
recurrent esophagus bleeding? 
METHOD
Literature searching was conducted on 7-14 
October 2018 in PubMed, Science Direct, EBSCOhost, 
Scopus, and ProQuest database. Keywords used 
included “Esophageal varices bleeding”, “Variceal 
band ligation”, and “Beta blocker” and any other words 
related or synonyms, then they were combined in a 
Boolean (Table 2). First attempt on literature searching 
had no specific limit. 
Through literature searching using the keywords 
mentioned above, 1813 articles were obtained. Articles 
Database Keywords First attempt Selection I Final results
PubMed (esophageal varices bleeding OR esophagus variceal 
rupture) AND (variceal band ligation OR endoscopic 
ligation) AND (beta blocker OR propranolol OR 
nadolol OR carvedilol)
525 13 1
Science Direct 300 8 1
EBSCOhost 181 10 1
Scopus 166 6 0
ProQuest 641 22 0
Figure 1. Flowchart of literature searching strategy
Volume 20, Number 2, August 2019 125
Endoscopic Variceal Ligation and ß-Blocker Combination Versus Ligation Monotherapy as Variceal Esophagus Bleeding Secondary Prevention
selection was conducted on some steps, including title 
and abstract selection, same articles selection, and 
full article selection. Title and abstract selection was 
based on inclusion criteria: therapeutic studies (meta-
analysis, systematic review, and randomized controlled 
trial) and relevance to clinical question. Exclusion 
criteria included more than ten years’ publication 
prior to this case report. From this selection stage, 59 
articles were obtained. After same article reduction, the 
full-text article selection was conducted. In this stage, 
these inclusion criteria were used: human study and 
secondary prevention on re-bleeding objective study. 
Exclusion criteria used were pharmacological therapy 
other than non-selective Beta Blocker, other than 
English-language articles, and studies on patients other 
than adults. In the end, the whole selection process 
resulted in three articles, including two meta-analysis 
and a randomized controlled trial. Literature searching 
and selection was summarized in Figure 1. 
Four articles obtained was critically appraised based 
on Oxford Center for Evidence Based Medicine year 
2011 for therapeutic study and systematic review. 
Critical appraisal examined on three aspects: validity, 
importance, and applicability of each article.
RESULTS
Critical appraisal on validity aspect shows that all 
articles are proven to be valid and continued to the 
importance aspect of critical appraisal. (Summarized in 
Table 5, 6, 7, and 8). Appraisal is conducted depended 
on the outcome of each study which discuss the efficacy 
of combination therapy as variceal bleeding secondary 
prevention. The primary outcomes include all causes 
mortality, mortality due to re-bleeding, all causes 
re-bleeding, and variceal esophagus re-bleeding. 
Secondary outcomes include varices eradication and 
varices recurrence. Outcome is measured as relative 
risk (RR), absolute risk reduction (ARR), relative risk 
reduction (RRR), number needed to treat (NNT), p 
value, odds ratio (OR), and P-score. 
Meta analysis by Ravipati et al shows that 
combination therapy is significantly able to decrease 
all causes and variceal esophagus re-bleeding. 
However, combination therapy is not significant in 
decreasing all cause and re-bleeding caused mortality 
of the patients. Only risk ratio and risk ratio reduction 
can be calculated from this article. Hence, the 
critical appraisal on importance aspect of this meta-
analysis is lack of data. In all aspects, relative risk of 
combination therapy usage are superior than ligation 
monotherapy. Especially in preventing varices re-
bleeding, combination therapy reaches RR = 0.601 
(95% CI: 0.440-0.820) with p < 0.001.
Outcome of the combination of endoscopic ligation 
with nadolol therapy in Shi et al. uses odd ratio value. 
This is due to lack of patients' data in each research of 
the meta-analysis. In this meta-analysis, combination 
therapy significantly lowers the acute re-bleeding 
Table 1. Critical appraisal of meta-analysis
Meta-Analysis
Validity Importance Applicability
Clinical 
Question
Searching 
strategy
Appropriate 
Inclusion Validity
Consis-
tency RR RRR p
Patient 
similarity
Feasibility 
in my 
setting
Benefits 
outweigh 
harms
Ravipati et al, 
2009
+ + + + + 0.601 (95 
CI: 0.440 - 
0.820)
0.399 0.001 + + +
Shi et al, 2017 + + + + + OR = 0.37 
(95%CI: 
0.16-0,86)
+ + +
RR: relative risk; RRR: relative risk reduction
Table 2. Critical appraisal of randomized controlled trial
RCT
Validity Importance Applicability
Randomized Similarity at start
Treated 
equally
All 
patients
Double 
blinded RR ARR RRR NNT p
Patient 
similarity
Feasibility 
in my 
setting
Benefits 
outweigh 
harms
Kumar et al, 
2009 + + + + + 0.89 0.02 11% 50 0.842 + + +
RRR: relative risk reduction; RRR: relative risk reduction; ARR: absolute risk reduction; NNT: number needed to treat
Figure 1. Forrest plot of Ravipati et al5
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Figure 2. Forrest plot of Shi et al6
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incidence. Nonetheless, combination therapy also 
fails to significantly lowers the mortality rate, even it 
increases the all-causes mortality of varices esophagus 
patient. Based on P-Score performance on variceal 
re-bleeding prevention, combination therapy is also 
superior (P-Score = 0.8526), compared to ligation 
monotherapy with 0.1919 P-Score. Superiority of 
P-Score are also in all other aspects of outcome. 
Critical appraisal on importance aspect in meta-
analysis by Shi et al. results in not sufficient of 
components, because there are not any control event 
rate (CER), experimental event rate (EER), RR, ARR, 
RRR, and NNT to calculate. 
Randomized Controlled Trial by Kumar et al gives 
sufficient importance aspect of critical appraisal. 
However, all of the results are not significant, based on 
the p value results. The primary outcomes, including 
re-bleeding rate and mortality rate, are decreased by 
combination therapy. Besides, combination therapy 
insignificantly increases variceal eradication and lowers 
varices recurrence, superior than ligation monotherapy, 
as secondary outcomes of this randomized controlled 
trial (RCT). 
Three articles are appraised on their applicability 
toward the patient in this case report. Applicability 
aspect is compared between patients in the literature 
and patient's characteristic of this case. Moreover, 
we appraised the benefits of combination therapy 
compared to potential side effects.
DISCUSSION
Both meta-analysis by Ravipati et al (2009) and Shi 
et al (2017) proves that combination therapy is able to 
significantly decrease the rate of all cause re-bleeding 
and variceal re-bleeding. This is also supported by 
superior P-score of combination therapy, compared 
to endoscopic ligation monotherapy.5,6 Mortality 
decrement also proven in combination therapy usage 
with superior P-Score than monotherapy, but with 
insignificant result. This superiority of combination 
therapy is supported by previous meta-analysis by 
de la Pena et al (2005) which proved the significant 
re-bleeding and mortality rate decrements.8,9 This 
result also corresponds to American Association 
for the Study of Liver Disease 2016 guidelines and 
recommendations where combination therapy is the 
first line management.10
Rationally, β-Blocker has capability to add protection 
effect towards variceal re-bleeding before the next 
variceal obliteration by endoscopic ligation and prevent 
variceal recurrences. It blocks β1receptor to lower cardiac 
output, then decreases portal tension.9,11-13 Moreover, β2 
receptor blockage causes α-adrenergic activation to 
stimulate splanchnic vasoconstriction and portal tension 
decrement.11-13 Propranolol is the most frequent to use 
as non-selective β-Blocker pharmacotherapy to be 
combined with endoscopic ligation.5-7 Besides, nadolol 
and carvedilol become alternatives. Propranolol is given 
2 x 10-20 mg per day, then titrated up to 40 mg if heart 
rate reaches 55 bpm.5,6 Full dosages usually reached 
in 2-3 weeks before the second Endoscopic ligation 
session. Therapy is evaluated every day in the first 
three months, then evaluated in the next 3 months.5-7 It 
is concluded that even combination therapy is the best 
alternative, more suitable trials are needed before the 
recommendation is set.5,6
Different result was stated in RCT by Kumar et 
al which proves insignificant combination therapy 
usage's benefit on all aspects. Seventy-five percent of 
patients had no respond from β-Blocker treatment.7 
Contraindications and severe complications happened 
in 30-40% of patients, where they gave no appropriate 
hemodynamic response to lower portal tension and 
prevent re-bleeding.11,12
Endoscopists conduct endoscopic ligation on 
gastroesophageal junction upward in 5-8 cm length 
and helical way.5,7 Ligation procedure use 5-8 elastic 
O-rings bands on varix in every session. Total ligation 
session is around 3-4 times until varices is completely 
obliterated.5,7 Moreover, there is no guidelines to oblige 
specific endoscopic ligations time interval, but usually 
is done in 1-2 weeks interval. However, new researches 
suggest 3-4 weeks interval for better result.7 The longer 
the ligation interval, the lower re-bleeding risk the 
patient has. This is caused by the longer period of time 
for partial varices recurrence to be more effectively 
located and ligated in the next session. Moreover, this 
decreases the bleeding caused by local ulcer in ligation 
site.5,7 Optimum endoscopic ligation result gives no 
necessity of pharmacological combination, where it will 
not give any more significant benefits. This hypothesis 
is strongly supported in RCT by Kumar et al.
Insignificant mortality rate decrement result may 
be explained in RCT of Kumar et al which shows no 
significant decrement in other severe complications, 
such as: ascites, hepatic encephalopathy, spontaneous 
bacterial peritonitis, hepatorenal syndrome, and other 
hospitalization needs of the patients.7,11,12 It is stated that 
β-Blocker has potential on increasing morbidity caused 
by its side effect, including headache, bradycardia, 
hypotension, and dyspnea. The unsuitability of patients 
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who get β-Blocker pharmacotherapy reaches up to 
30-40%.7 
CONCLUSION
Based on critical appraisal on two meta-analysis and 
one randomized controlled trial, correlation between 
combination therapy and secondary prevention of 
variceal esophagus bleeding is still inconsistent. 
However, we still recommend this combination therapy 
based on two highest evidence level of literatures, 
which states significant results on variceal re-bleeding 
decrement. Moreover, further examination is needed 
in 12-24 hours before initiating therapy to check any 
contraindications and patient's suitability to non-
selective β-Blocker therapy. We also conclude that 
combination therapy will not decrease mortality rate of 
the patient with post cirrhotic acute variceal esophagus 
bleeding. Hence, other treatments are needed to alter 
the cirrhotic progression and its other complications 
to lower the mortality rate. 
We suggest other further research to study 
the justification between combination therapy's 
complications and its cost-effectiveness aspect for 
variceal esophagus bleeding secondary prevention. 
Thus, we can evaluate comprehensively to be basic 
principal for physician's clinical judgement and 
patient's preference in deciding which modality to 
prevent variceal esophagus re-bleeding.
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